The once hard-to-find injection gained widespread popularity for a reason unrelated to its original purpose. Ozempic, a prescription medication for type 2 diabetes, has become known globally for its weight-loss effects.
In 2023, a trend began to emerge on social media: weight loss with Ozempic. Influencers began posting dramatic ‘before and after’ results, leading to surging public interest. In response, demand for the drug skyrocketed, overwhelming supply chains and creating a shortage that affected people who genuinely need the medication to manage their diabetes.
RTL received multiple testimonies after launching a public call on its website. ‘Marcel’ lost 25kg using Ozempic, Cathy nearly 20kg, Nadine 8kg, and Jean-Paul 32kg, testimonies reflecting a much wider trend.
As global demand surged, Luxembourg, like many other countries, took action. In January 2024, a ministerial decree limited the prescription and sale of Ozempic and similar drugs. From that point on, they could only be prescribed to people with type 2 diabetes, in line with the approved medical indications.
Two years on from the start of the phenomenon, the situation has largely stabilised. While demand remains high, increased production has helped rebuild pharmacy stocks across the country. As a result, the Health Directorate lifted the restriction in June 2025.
In an interview with RTL in November 2025, Dr Anna Chioti, head of the pharmacies and medicines division at the Health Directorate, reiterated the department’s position:
“It is legal to prescribe it for other uses, but it is not recommended. All medicines must be prescribed in accordance with their indications – that is, the reason for which they were placed on the market. In the case of Ozempic, that is for type 2 diabetes. Furthermore, there are currently enough alternatives on the market that are indicated for weight loss”, she said.
She also noted that the drug is only available on prescription due to possible serious side effects, and warned the public not to buy it online or take it without medical supervision.
However, the World Health Organisation (WHO) struck a different tone in a statement issued on 1 December 2025. The organisation announced that it would recommend the use of drugs such as Ozempic, currently indicated for type 2 diabetes, for the treatment of overweight patients.
What drives this continuing trend, despite medical concerns and official guidelines? One person who responded to RTL’s call spoke candidly about her journey.
Sandrine Massard weighed 135kg just four years ago. By the end of 2025, she weighed just over 100.
Her experience began with a diagnosis of polycystic ovary syndrome (PCOS), a hormonal disorder that can cause insulin resistance and weight gain. She was prescribed Ozempic in 2022 and began on a low dose. Her full testimony including the impacts of the treatment is available in RTL.lu’s Luxembourgish report below.
